Knopp Biosciences   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Pittsburgh PA United States (2005)

Organization Overview

First Clinical Trial
2008
NCT00647296
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Knopp Biosciences

Active Ingredients

Drugs in Phase 3 Trials (1)

dexpramipexole (12 trials)

Drugs in Phase 2 Trials (1)

pramipexole (mirapex) (2 trials)

Drugs in Phase 1 Trials (3)

cimetidine (tagamet) (1 trial)

moxifloxacin (avelox) (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Asthma (Phase 2)

Chronic Disease (Phase 2)

Eosinophilia (Phase 2)

Hypereosinophilic Syndrome (Phase 2)

Motor Neuron Disease (Phase 3)

Nasal Polyps (Phase 2)

Polyps (Phase 2)

Pulmonary Eosinophilia (Phase 2)

Renal Insufficiency (Phase 1)

Sclerosis (Phase 3)

Sinusitis (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 5